NK/T Cell Lymphoma Clinical Trial
Official title:
Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
n/a
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04899414 -
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT05627856 -
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05208853 -
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
|
Early Phase 1 | |
Withdrawn |
NCT04230330 -
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04004637 -
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04038411 -
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
|
Phase 4 |